Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Follicle Stimulating Hormone Market Forecast: What Value Will The Market Reach By 2030?
The follicle stimulating hormone market has seen consistent expansion in recent years. It is projected to increase from $2.12 billion in 2025 to $2.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.8%. The historic period’s growth can be attributed to progress in recombinant hormone production, a rise in infertility cases, the expansion of healthcare infrastructure, heightened awareness of fertility treatments, and the adoption of urinary FSH formulations.
The market for follicle-stimulating hormone is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $2.76 billion, demonstrating a compound annual growth rate (CAGR) of 5.7%. This predicted growth is largely due to advancements in FSH delivery systems, the proliferation of assisted reproductive technology (ART) centers, the wider adoption of telehealth services for fertility care, governmental backing for infertility solutions, and a rising preference for individualized approaches in reproductive medicine. Key developments during this period will encompass tailored fertility interventions, greater utilization of recombinant hormones, the incorporation of telemedicine into fertility services, heightened emphasis on female reproductive health education, and the continued establishment of assisted reproductive technology (ART) clinics.
Get A Free Sample Report With In-Depth Market Insights:
Follicle Stimulating Hormone Market Growth Catalysts And Demand Drivers
The follicle-stimulating hormone market is projected to experience growth in the coming years, primarily propelled by the rising adoption of assisted reproductive technology. Assisted Reproductive Technology (ART) refers to medical procedures designed to help individuals or couples achieve conception when conventional methods have been unsuccessful. The application of follicle-stimulating hormone within ART is a well-established therapeutic approach aimed at enhancing the probability of a successful pregnancy for those facing reproductive challenges. For instance, in March 2024, the US department of Health and Human services, a US-based government agency, reported that the use of ART escalates with maternal age. In 2023, ART played a role in 9% of live births among women aged 40-45, a proportion that significantly increased to nearly one-third for women 45 and older. Furthermore, ART usage exhibits regional variations across the U.S. Hence, the increasing integration of assisted reproductive technology is a significant factor driving the follicle-stimulating hormone market.
Follicle Stimulating Hormone Market Segment Trends And Revenue Contributors
The follicle stimulating hormone market covered in this report is segmented –
1) By Type: Recombinant FSH, Urinary FSH
2) By Application: Infertility Treatment, Assisted Reproductive Technology (ART), Other Applications
3) By End-Users: Infertility Center, Hospitals, Other End-Users
Subsegments:
1) By Recombinant FSH: Pure Recombinant FSH, Mixed Recombinant FSH Formulations
2) By Urinary FSH: Purified Urinary FSH, Urinary FSH Combined With Other Hormones
Follicle Stimulating Hormone Market Trends Shaping Long-Term Demand
Leading companies in the follicle-stimulating hormone market are developing advanced products, such as multi-hormone at-home diagnostic testing systems, to provide enhanced accuracy, continuous monitoring, and patient-centric understanding of hormone health and reproductive function. These integrated, user-friendly platforms allow for the measurement of FSH along with other crucial reproductive hormones through non-invasive sampling, thereby enabling real-time tracking, personalized health assessments, and improved clinical decision-making without the necessity of in-clinic visits. As an illustration, in July 2024, Proov, a US-based women’s health company, unveiled its Proov Empower Perimenopause Testing System. Proov Empower delivers comprehensive and tailored insights into how fluctuating hormones influence a woman’s overall health and well-being. This non-invasive, multi-time point urine test evaluates four key hormones FSH, estrogen marker E1G, progesterone marker PdG, and LH, which impact symptoms and the perimenopause experience. Through periodic retesting, Proov Empower assists women in tracking hormone variations and associated symptoms, serving as an important guide during the menopause transition.
Follicle Stimulating Hormone Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the follicle stimulating hormone market are Pfizer Inc., Sanofi S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Emcure Pharmaceuticals Ltd., IBSA Group, Taj Pharmaceuticals Ltd., Trumac Healthcare, Midas Pharma GmbH, Shanghai Techwell Biopharmaceutical Co. Ltd., Livzon Pharmaceutical Group Inc., Anhui Anke Biotechnology Group Co. Ltd., LG Chem Life Sciences, Genpharm Inc., Biogenix Inc. Pvt. Ltd.
View The Full Follicle Stimulating Hormone Market Report:
Follicle Stimulating Hormone Market Top Region By Revenue And Market Share
North America was the largest region in the follicle stimulating hormone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
